Year: 2022

Amsterdam/’s-Hertogenbosch, the Netherlands, 27 December 2022 The Dutch Central Bank (DNB) has set the MREL requirements (Minimum Requirement for own funds and Eligible Liabilities) for Van Lanschot Kempen. These MREL requirements, which determine the minimum amount of equity and liabilities a bank must have, apply from 1 January 2024. They are equal to the requirements at that moment in force under the Supervisory Review and Evaluation Process (SREP). The current SREP requirements are 5.7% for the CET 1 ratio, 8.6% for the Tier 1 ratio and 11.5% for the total capital ratio. At the end of the third quarter, Van Lanschot Kempen’s CET 1 ratio was 19.2%. This is well above the current SREP requirements; and well above its own target of 15% plus an M&A add-on of 2.5% for acquisitions. DNB has also determined that Van Lanschot Kempen...

Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and Asia NANORAY-312 now has sites activated across 80 sites globally Phase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected in 2H 2024PARIS and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (“LA-HNSCC”) who are ineligible for platinum-based...

INVL Technology (hereinafter – the Company) informs that under the provision of the Law on Collective Investment Undertakings of the Republic of Lithuania (hereinafter – CIU), the Company operating under the CIU is under an obligation to have a valid prospectus (hereinafter – the Prospectus) prepared in accordance with the requirements of the CIU or of the Law on Securities of the Republic of Lithuania (hereinafter – LS). In order to meet the above-mentioned requirement, in September 2019 the Company’s management company INVL Asset Management, UAB (hereinafter – the Management company) prepared a Prospectus in compliance with CIU. Considering that at the time of publication of the information there are no grounds that the Company should prepare and own a prospectus complying with the requirements of the LS, on 22 December 2022,...

INVL Technology plans to publish information to investors in 2023 in accordance with the following calendar: 6 April 2023 – audited financial reports and annual report. 28 April 2023 – Net Asset Value and factsheet for 3 months of 2023. 28 August 2023 – Net Asset Value and semi–annual report of 2023. 30 October 2023 – Net Asset Value and factsheet for 9 months of 2023. The person authorized to provide additional information: Kazimieras TonkūnasINVL Technology Managing Partner E-mail k.tonkunas@invltechnology.lt

Appointment Part of Apollo’s Continued Buildout in Japan and Long-term Commitment to Providing Fixed Income Replacement and Alternative Investment Solutions for the Japanese Market NEW YORK, Dec. 26, 2022 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Tatsuo Tanaka has been named as Japan Chair to Apollo. Mr. Tanaka is a 50-year veteran of the banking and finance industry in Japan, having held various senior positions in leading financial institutions, including as Deputy President of MUFG Bank and Mitsubishi UFJ Financial Group, Chairman of Union Bank and, most recently, Chairman of Citigroup Japan. Mr. Tanaka’s appointment reflects Apollo’s continued growth in its asset management and retirement services businesses in Japan.   “This new role is a reflection of the importance we place on Japan and the growth opportunities...

Amsterdam, Netherlands, 26 December 2022 19:30 CET: Following the announcement made on 21 December 2022 related to the Court order granting the Company permission to convene the Scheme Meeting, VEON Ltd. (NASDAQ, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, and its subsidiary, VEON Holdings B.V. (the “Company”) hereby give notice that the OFAC License referred to in the previous announcement has been granted, such that the Company is satisfied that it has obtained all necessary OFAC related Authorisations for the Scheme. The OFAC License authorises all noteholders (and their funds, fund managers, investment advisors or subadvisors), financial institutions, clearing and trading systems, trustees, paying and security agents, registrars, and other service providers, intermediaries,...

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces a new exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, for toripalimab in the Middle East and North Africa (MENA). Under the terms of the agreement, Hikma is granted an exclusive license to develop and commercialize toripalimab injection in all its MENA markets. In addition, Junshi Biosciences will grant the right of first negotiation to Hikma for the future commercialization of three under development drugs in MENA. Toripalimab is an innovative anti-PD-1 monoclonal...

– FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA – – Junshi Biosciences and Coherus are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC in the U.S. as quickly as possible – SHANGHAI, China and REDWOOD CITY, Calif., Dec. 25, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that the companies have not received an action letter from the U.S. Food and Drug Administration (FDA, the Agency) regarding the Biologics License Application (BLA) for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic...

CALGARY, Alberta, Dec. 24, 2022 (GLOBE NEWSWIRE) — Jura Energy Corporation (“Jura”) is pleased to announce today that repair and testing of the Zarghun South sale gas pipeline, which was damaged due to flash floods, have been completed and the supply of sale gas has resumed from the Zarghun South Lease. The Zarghun South Lease covers an area of 124.22 square kilometers in the western part of the Sulaiman Fold and Thrust Belt of the Middle Indus Basin. It is strategically located near the gas demand centre of the city of Quetta. Jura holds a 40% working interest in the Zarghun South Lease, which is operated by Mari Petroleum Company Limited. Jura also provides an update with regard to a dispute between its wholly-owned subsidiaries, Spud Energy Pty Limited (“SEPL”) and Frontier Holdings Limited (“FHL”), with Petroleum Exploration...